Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold

被引:9
|
作者
Baumeister, Soeren [1 ]
Schepmann, Dirk [1 ]
Wuensch, Bernhard [1 ,2 ]
机构
[1] Univ Munster, Inst Pharmazeut & Med Chem, Corrensstr 48, D-48149 Munster, Germany
[2] Westfalische Wilhelms Univ Munster, Cells In Mot Cluster Excellence EXC CiM 1003, Munster, Germany
关键词
D-ASPARTATE RECEPTOR; PHARMACOLOGICAL EVALUATION; NR2B SUBUNIT; NMDA-RECEPTORS; IFENPRODIL; AFFINITY; ANTAGONISTS; EXPRESSION; PHOSPHORYLATION; EXCITOTOXICITY;
D O I
10.1039/c8md00545a
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The involvement of NMDA receptors containing the GluN2B subunit in neurodegenerative disorders including Alzheimer's and Parkinson's disease renders this NMDA receptor subtype an interesting pharmacological target. The aim of this study was the bioisosteric replacement of benzene, methoxybenzene and aniline moieties of known potent GluN2B selective NMDA receptor antagonists by a thiophene ring. In a nine-step synthesis starting from commercially available propionic acid 9 the thiophene derivative 7a was obtained as a bioisostere of the potent GluN2B ligands cis-3 and trans-3. [7] Annuleno.b] thiophene 8a without a benzylic OH moiety was prepared in a six-step synthesis starting from carboxylic acid 18. 8a represents a bioisostere of potent GluN2B ligands 4 and 5. [7] Annulenothiophene 8a without a benzylic OH moiety reveals approx. 8-fold higher GluN2B affinity (Ki = 26 nM) than the analogous thiophene derivative 7a with a benzylic OH moiety (Ki = 204 nM). Both thiophene bioisosteres show a slight preference for GluN2B receptors over both s receptors. The data indicate that the bioisosteric replacement of benzene or substituted benzene rings by a thiophene ring is well tolerated by the NMDA receptor. Furthermore, the benzylic OH moiety seems not to be essential for high GluN2B affinity.
引用
收藏
页码:315 / 325
页数:11
相关论文
共 33 条
  • [11] Design, Synthesis, Pharmacological Evaluation and Docking Studies of GluN2B-Selective NMDA Receptor Antagonists with a Benzo[7]annulen-7-amine Scaffold
    Gawaskar, Sandeep
    Temme, Louisa
    Schreiber, Julian A.
    Schepmann, Dirk
    Bonifazi, Alessandro
    Robaa, Dina
    Sippl, Wolfgang
    Strutz-Seebohm, Nathalie
    Seebohm, Guiscard
    Wuensch, Bernhard
    CHEMMEDCHEM, 2017, 12 (15) : 1212 - 1222
  • [12] Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents
    Zampieri, Daniele
    Fortuna, Sara
    Calabretti, Antonella
    Romano, Maurizio
    Menegazzi, Renzo
    Schepmann, Dirk
    Wuensch, Bernhard
    Collina, Simona
    Zanon, Davide
    Mamolo, Maria Grazia
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 180 : 268 - 282
  • [13] Synthesis and Pharmacological Evaluation of Enantiomerically Pure GluN2B Selective NMDA Receptor Antagonists
    Boergel, Frederik
    Szermerski, Marina
    Schreiber, Julian A.
    Temme, Louisa
    Strutz-Seebohm, Nathalie
    Lehmkuhl, Kirstin
    Schepmann, Dirk
    Ametamey, Simon M.
    Seebohm, Guiscard
    Schmidt, Thomas J.
    Wuensch, Bernhard
    CHEMMEDCHEM, 2018, 13 (15) : 1580 - 1587
  • [14] Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains
    Swanger, Sharon A.
    Chen, Wenjuan
    Wells, Gordon
    Burger, Pieter B.
    Tankovic, Anel
    Bhattacharya, Subhrajit
    Strong, Katie L.
    Hu, Chun
    Kusumoto, Hirofumi
    Zhang, Jing
    Adams, David R.
    Millichap, John J.
    Petrovski, Slave
    Traynelis, Stephen F.
    Yuan, Hongjie
    AMERICAN JOURNAL OF HUMAN GENETICS, 2016, 99 (06) : 1261 - 1280
  • [15] Mapping the high-affinity binding domain of 5-substituted benzimidazoles to the proximal N-terminus of the GluN2B subunit of the NMDA receptor
    Wee, X-K
    Ng, K-S
    Leung, H-W
    Cheong, Y-P
    Kong, K-H
    Ng, F-M
    Soh, W.
    Lam, Y.
    Low, C-M
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (02) : 449 - 461
  • [16] Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists
    Wagner, Marina
    Schepmann, Dirk
    Ametamey, Simon M.
    Wuensch, Bernhard
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (16) : 3559 - 3567
  • [17] Phenol-Benzoxazolone bioisosteres: Synthesis and biological evaluation of tricyclic GluN2B-selective N-methyl- d-aspartate receptor antagonists
    Markus, Alexander
    Schreiber, Julian A.
    Goerges, Gunnar
    Frehland, Bastian
    Seebohm, Guiscard
    Schepmann, Dirk
    Wuensch, Bernhard
    ARCHIV DER PHARMAZIE, 2022, 355 (09)
  • [18] In vitro and in vivo biotransformation of WMS-1410, a potent GluN2B selective NMDA receptor antagonist
    Falck, Evamaria
    Begrow, Frank
    Verspohl, Eugen J.
    Wuensch, Bernhard
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, 94 : 36 - 44
  • [19] Pharmacokinetic properties of enantiomerically pure GluN2B selective NMDA receptor antagonists with 3-benzazepine scaffold
    Boergel, Frederik
    Galla, Fabian
    Lehmkuhl, Kirstin
    Schepmann, Dirk
    Ametamey, Simon M.
    Wuensch, Bernhard
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 172 : 214 - 222
  • [20] Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation
    Temme, Louisa
    Frehland, Bastian
    Schepmann, Dirk
    Robaa, Dina
    Sippl, Wolfgang
    Wuesch, Bernhard
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 144 : 672 - 681